Elena Ambrogini
Concepts (231)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Osteogenesis | 7 | 2023 | 377 | 1.670 |
Why?
| Bone Density | 7 | 2023 | 416 | 1.660 |
Why?
| Osteoblasts | 12 | 2023 | 514 | 1.610 |
Why?
| Phospholipids | 2 | 2021 | 63 | 1.540 |
Why?
| Scavenger Receptors, Class B | 2 | 2023 | 10 | 1.090 |
Why?
| Bone and Bones | 7 | 2023 | 515 | 1.080 |
Why?
| Bone Diseases, Metabolic | 2 | 2023 | 84 | 0.970 |
Why?
| Osteoporosis | 4 | 2020 | 164 | 0.820 |
Why?
| Forkhead Transcription Factors | 5 | 2016 | 118 | 0.730 |
Why?
| Hyperparathyroidism, Primary | 6 | 2009 | 50 | 0.680 |
Why?
| Immunoglobulin M | 1 | 2018 | 65 | 0.640 |
Why?
| Single-Chain Antibodies | 1 | 2018 | 28 | 0.640 |
Why?
| Epitopes | 1 | 2018 | 89 | 0.640 |
Why?
| Aging | 3 | 2021 | 784 | 0.610 |
Why?
| Mice | 17 | 2023 | 6428 | 0.600 |
Why?
| Animals | 22 | 2023 | 14409 | 0.530 |
Why?
| Oxidative Stress | 6 | 2011 | 958 | 0.510 |
Why?
| Mice, Knockout | 5 | 2022 | 927 | 0.510 |
Why?
| Mice, Transgenic | 4 | 2021 | 658 | 0.420 |
Why?
| Bone Resorption | 5 | 2023 | 328 | 0.360 |
Why?
| Osteoclasts | 5 | 2023 | 469 | 0.360 |
Why?
| Parathyroid Neoplasms | 6 | 2008 | 44 | 0.340 |
Why?
| Oxidation-Reduction | 3 | 2020 | 383 | 0.340 |
Why?
| Estrogens | 5 | 2012 | 244 | 0.320 |
Why?
| Wnt Signaling Pathway | 3 | 2013 | 94 | 0.310 |
Why?
| Female | 27 | 2022 | 28471 | 0.290 |
Why?
| Estrogen Receptor alpha | 3 | 2012 | 95 | 0.280 |
Why?
| Cells, Cultured | 6 | 2018 | 1737 | 0.270 |
Why?
| Gene Deletion | 3 | 2016 | 293 | 0.270 |
Why?
| Stem Cells | 3 | 2016 | 194 | 0.260 |
Why?
| Osteoporosis, Postmenopausal | 1 | 2005 | 36 | 0.250 |
Why?
| Tumor Suppressor Proteins | 5 | 2008 | 141 | 0.250 |
Why?
| Mice, Inbred C57BL | 6 | 2018 | 2001 | 0.240 |
Why?
| Male | 18 | 2022 | 27347 | 0.240 |
Why?
| Apoptosis | 7 | 2011 | 1302 | 0.240 |
Why?
| Autoimmune Diseases | 1 | 2005 | 115 | 0.230 |
Why?
| Hyperparathyroidism | 4 | 2004 | 50 | 0.220 |
Why?
| Mechanotransduction, Cellular | 1 | 2023 | 35 | 0.220 |
Why?
| Cell Differentiation | 4 | 2020 | 720 | 0.220 |
Why?
| Adipogenesis | 2 | 2020 | 54 | 0.220 |
Why?
| Receptors, Scavenger | 1 | 2022 | 28 | 0.210 |
Why?
| T-Lymphocytes | 1 | 2005 | 374 | 0.210 |
Why?
| Parathyroidectomy | 3 | 2009 | 75 | 0.210 |
Why?
| Hypothyroidism | 2 | 2021 | 53 | 0.200 |
Why?
| Parathyroid Hormone | 3 | 2010 | 196 | 0.200 |
Why?
| Cell Proliferation | 5 | 2018 | 1097 | 0.200 |
Why?
| Osteocytes | 1 | 2023 | 219 | 0.190 |
Why?
| Thyroxine | 1 | 2021 | 47 | 0.190 |
Why?
| Antibodies, Neutralizing | 1 | 2020 | 76 | 0.190 |
Why?
| Reactive Oxygen Species | 4 | 2014 | 491 | 0.170 |
Why?
| Shc Signaling Adaptor Proteins | 4 | 2011 | 27 | 0.170 |
Why?
| Adenoma | 6 | 2008 | 142 | 0.160 |
Why?
| Androgens | 2 | 2022 | 68 | 0.140 |
Why?
| Hypertension | 1 | 2022 | 565 | 0.140 |
Why?
| Glucocorticoids | 2 | 2011 | 234 | 0.140 |
Why?
| Lipoproteins, LDL | 1 | 2018 | 195 | 0.140 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2011 | 435 | 0.140 |
Why?
| Pregnancy Complications | 1 | 2021 | 387 | 0.140 |
Why?
| Diet, High-Fat | 1 | 2018 | 216 | 0.140 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 541 | 0.140 |
Why?
| Hydrogen Peroxide | 2 | 2014 | 142 | 0.140 |
Why?
| Calcium | 2 | 2008 | 434 | 0.130 |
Why?
| Wnt Proteins | 3 | 2011 | 110 | 0.130 |
Why?
| Diabetes Mellitus, Experimental | 1 | 2016 | 140 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 2 | 2014 | 206 | 0.130 |
Why?
| Aged | 9 | 2023 | 10060 | 0.130 |
Why?
| Signal Transduction | 3 | 2010 | 1752 | 0.120 |
Why?
| Catalase | 1 | 2014 | 74 | 0.120 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2016 | 202 | 0.120 |
Why?
| Middle Aged | 12 | 2021 | 13082 | 0.120 |
Why?
| Humans | 22 | 2023 | 54391 | 0.120 |
Why?
| Periosteum | 1 | 2012 | 20 | 0.110 |
Why?
| Cell Cycle Proteins | 2 | 2013 | 198 | 0.110 |
Why?
| Receptors, Calcium-Sensing | 2 | 2008 | 4 | 0.100 |
Why?
| Prednisolone | 1 | 2011 | 57 | 0.100 |
Why?
| Osteoprotegerin | 2 | 2023 | 57 | 0.090 |
Why?
| Protein Kinase C | 1 | 2010 | 65 | 0.090 |
Why?
| Sulfaphenazole | 1 | 2009 | 4 | 0.090 |
Why?
| Parathyroid Glands | 2 | 2007 | 39 | 0.090 |
Why?
| Transgenes | 1 | 2010 | 55 | 0.090 |
Why?
| Family Health | 2 | 2008 | 85 | 0.090 |
Why?
| Dexamethasone | 1 | 2011 | 435 | 0.090 |
Why?
| Spinal Fractures | 1 | 2009 | 41 | 0.080 |
Why?
| PPAR gamma | 1 | 2009 | 81 | 0.080 |
Why?
| Hypercalcemia | 1 | 2008 | 36 | 0.080 |
Why?
| NF-kappa B | 1 | 2010 | 336 | 0.080 |
Why?
| Estradiol | 1 | 2010 | 219 | 0.080 |
Why?
| Postmenopause | 1 | 2009 | 102 | 0.080 |
Why?
| Germ-Line Mutation | 2 | 2007 | 68 | 0.080 |
Why?
| Lipid Metabolism | 1 | 2009 | 194 | 0.080 |
Why?
| Up-Regulation | 1 | 2010 | 509 | 0.080 |
Why?
| Endpoint Determination | 1 | 2007 | 30 | 0.080 |
Why?
| Nitric Oxide | 1 | 2009 | 298 | 0.080 |
Why?
| Aged, 80 and over | 3 | 2022 | 3431 | 0.070 |
Why?
| Absorptiometry, Photon | 1 | 2007 | 174 | 0.070 |
Why?
| Interpersonal Relations | 1 | 2007 | 115 | 0.070 |
Why?
| Adult | 11 | 2021 | 14207 | 0.070 |
Why?
| Data Interpretation, Statistical | 1 | 2007 | 177 | 0.070 |
Why?
| Spine | 1 | 2007 | 112 | 0.070 |
Why?
| X-Ray Microtomography | 2 | 2016 | 81 | 0.070 |
Why?
| Disease Models, Animal | 2 | 2016 | 1647 | 0.070 |
Why?
| Loss of Heterozygosity | 4 | 2007 | 97 | 0.070 |
Why?
| Phenotype | 2 | 2013 | 819 | 0.070 |
Why?
| Major Histocompatibility Complex | 1 | 2005 | 14 | 0.070 |
Why?
| Graves Disease | 1 | 2005 | 23 | 0.060 |
Why?
| Histocompatibility Antigens Class II | 1 | 2005 | 44 | 0.060 |
Why?
| Hepatitis, Autoimmune | 1 | 2005 | 29 | 0.060 |
Why?
| Infarction | 1 | 2004 | 15 | 0.060 |
Why?
| Femur | 2 | 2016 | 144 | 0.060 |
Why?
| Echocardiography | 1 | 2007 | 392 | 0.060 |
Why?
| Lymphocyte Activation | 1 | 2005 | 197 | 0.060 |
Why?
| Transforming Growth Factor beta | 1 | 2005 | 158 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2009 | 1063 | 0.060 |
Why?
| Congenital Hypothyroidism | 1 | 2003 | 4 | 0.060 |
Why?
| Symporters | 1 | 2003 | 18 | 0.060 |
Why?
| Transcription Factors | 3 | 2013 | 622 | 0.060 |
Why?
| Ion Channels | 1 | 2023 | 75 | 0.060 |
Why?
| Multiple Endocrine Neoplasia Type 1 | 1 | 2002 | 4 | 0.050 |
Why?
| Immunization, Passive | 1 | 2022 | 35 | 0.050 |
Why?
| Proteins | 1 | 2004 | 376 | 0.050 |
Why?
| Prospective Studies | 1 | 2007 | 2606 | 0.050 |
Why?
| Quality of Life | 1 | 2007 | 924 | 0.050 |
Why?
| Arachidonate 15-Lipoxygenase | 2 | 2010 | 17 | 0.050 |
Why?
| Arachidonate 12-Lipoxygenase | 2 | 2010 | 17 | 0.050 |
Why?
| Treatment Outcome | 2 | 2022 | 5612 | 0.050 |
Why?
| Gene Knock-In Techniques | 2 | 2010 | 30 | 0.050 |
Why?
| Multienzyme Complexes | 2 | 2010 | 41 | 0.050 |
Why?
| Patient Safety | 1 | 2021 | 121 | 0.050 |
Why?
| Enzyme Activation | 2 | 2010 | 328 | 0.040 |
Why?
| Oxygen | 1 | 2022 | 361 | 0.040 |
Why?
| Phosphorylation | 2 | 2010 | 613 | 0.040 |
Why?
| Transcription, Genetic | 2 | 2010 | 418 | 0.040 |
Why?
| Patient Education as Topic | 1 | 2021 | 311 | 0.040 |
Why?
| Mutation, Missense | 2 | 2008 | 117 | 0.040 |
Why?
| Hospitalization | 1 | 2022 | 704 | 0.040 |
Why?
| Immunohistochemistry | 3 | 2007 | 1090 | 0.040 |
Why?
| Risk Factors | 2 | 2021 | 3937 | 0.040 |
Why?
| Age Factors | 1 | 2020 | 1199 | 0.040 |
Why?
| Integrases | 1 | 2016 | 45 | 0.040 |
Why?
| Cell Line | 2 | 2010 | 1152 | 0.040 |
Why?
| COS Cells | 2 | 2008 | 78 | 0.040 |
Why?
| Cell Lineage | 1 | 2016 | 93 | 0.040 |
Why?
| Carcinoma | 2 | 2008 | 154 | 0.040 |
Why?
| Organ Size | 1 | 2016 | 237 | 0.030 |
Why?
| Risk Assessment | 1 | 2021 | 1362 | 0.030 |
Why?
| Proto-Oncogene Proteins | 2 | 2007 | 169 | 0.030 |
Why?
| Sensitivity and Specificity | 2 | 2009 | 922 | 0.030 |
Why?
| Transfection | 2 | 2008 | 399 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2021 | 1696 | 0.030 |
Why?
| Recurrence | 2 | 2007 | 692 | 0.030 |
Why?
| Arkansas | 1 | 2021 | 2100 | 0.030 |
Why?
| DNA Mutational Analysis | 2 | 2007 | 217 | 0.030 |
Why?
| Glucose | 1 | 2016 | 366 | 0.030 |
Why?
| DNA Primers | 1 | 2014 | 225 | 0.030 |
Why?
| Sequence Analysis, DNA | 2 | 2007 | 274 | 0.030 |
Why?
| Time Factors | 1 | 2021 | 3210 | 0.030 |
Why?
| Mice, 129 Strain | 1 | 2013 | 49 | 0.030 |
Why?
| Gene Knockout Techniques | 1 | 2013 | 45 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 206 | 0.030 |
Why?
| Adolescent | 2 | 2021 | 6900 | 0.030 |
Why?
| Pregnancy | 1 | 2021 | 2639 | 0.030 |
Why?
| Mice, Mutant Strains | 1 | 2012 | 84 | 0.030 |
Why?
| RANK Ligand | 1 | 2014 | 183 | 0.030 |
Why?
| Analysis of Variance | 1 | 2014 | 634 | 0.030 |
Why?
| Blotting, Western | 1 | 2014 | 684 | 0.030 |
Why?
| Adiposity | 1 | 2013 | 142 | 0.030 |
Why?
| MAP Kinase Kinase 4 | 1 | 2011 | 34 | 0.030 |
Why?
| Bone Marrow | 1 | 2013 | 414 | 0.020 |
Why?
| beta Catenin | 1 | 2011 | 102 | 0.020 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 176 | 0.020 |
Why?
| Young Adult | 1 | 2021 | 4318 | 0.020 |
Why?
| United States | 1 | 2022 | 5208 | 0.020 |
Why?
| Smad1 Protein | 1 | 2010 | 6 | 0.020 |
Why?
| Oxidants | 1 | 2010 | 64 | 0.020 |
Why?
| Glutathione Reductase | 1 | 2010 | 15 | 0.020 |
Why?
| Chimera | 1 | 2010 | 13 | 0.020 |
Why?
| omega-N-Methylarginine | 1 | 2009 | 11 | 0.020 |
Why?
| Bone Morphogenetic Protein 2 | 1 | 2010 | 51 | 0.020 |
Why?
| Gene Targeting | 1 | 2010 | 32 | 0.020 |
Why?
| Biological Factors | 1 | 2009 | 13 | 0.020 |
Why?
| Ascorbic Acid | 1 | 2009 | 33 | 0.020 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 101 | 0.020 |
Why?
| Ovariectomy | 1 | 2010 | 127 | 0.020 |
Why?
| Organ Specificity | 1 | 2010 | 126 | 0.020 |
Why?
| Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 70 | 0.020 |
Why?
| Validation Studies as Topic | 1 | 2009 | 10 | 0.020 |
Why?
| Cell Count | 1 | 2009 | 181 | 0.020 |
Why?
| Vasodilation | 1 | 2009 | 106 | 0.020 |
Why?
| Italy | 1 | 2008 | 24 | 0.020 |
Why?
| Aldehydes | 1 | 2009 | 97 | 0.020 |
Why?
| Cattle | 1 | 2009 | 225 | 0.020 |
Why?
| RNA Splice Sites | 1 | 2008 | 12 | 0.020 |
Why?
| Bone Marrow Cells | 1 | 2010 | 232 | 0.020 |
Why?
| Alleles | 1 | 2009 | 277 | 0.020 |
Why?
| Microscopy, Confocal | 1 | 2008 | 110 | 0.020 |
Why?
| Antioxidants | 1 | 2010 | 297 | 0.020 |
Why?
| Microscopy, Fluorescence | 1 | 2008 | 198 | 0.020 |
Why?
| Endothelium, Vascular | 1 | 2009 | 288 | 0.020 |
Why?
| Mutation | 2 | 2006 | 1504 | 0.020 |
Why?
| Cyclin D1 | 1 | 2007 | 60 | 0.020 |
Why?
| Cell Survival | 1 | 2009 | 657 | 0.020 |
Why?
| Macrophages | 1 | 2010 | 404 | 0.020 |
Why?
| DNA, Neoplasm | 1 | 2007 | 171 | 0.020 |
Why?
| RNA, Messenger | 1 | 2010 | 1203 | 0.020 |
Why?
| Hyperplasia | 1 | 2006 | 107 | 0.020 |
Why?
| Prevalence | 1 | 2009 | 1025 | 0.020 |
Why?
| Pedigree | 1 | 2006 | 146 | 0.020 |
Why?
| Case-Control Studies | 1 | 2009 | 1229 | 0.020 |
Why?
| Liver Function Tests | 1 | 2005 | 43 | 0.020 |
Why?
| Methylprednisolone | 1 | 2005 | 38 | 0.020 |
Why?
| Algorithms | 1 | 2009 | 697 | 0.020 |
Why?
| Prednisone | 1 | 2005 | 111 | 0.020 |
Why?
| Remission, Spontaneous | 1 | 2004 | 20 | 0.020 |
Why?
| Base Sequence | 1 | 2006 | 719 | 0.020 |
Why?
| Lymphocytes | 1 | 2005 | 168 | 0.020 |
Why?
| Iodides | 1 | 2003 | 3 | 0.010 |
Why?
| Predictive Value of Tests | 1 | 2007 | 1045 | 0.010 |
Why?
| Introns | 1 | 2003 | 49 | 0.010 |
Why?
| Heterozygote | 1 | 2003 | 96 | 0.010 |
Why?
| Neck | 1 | 2004 | 116 | 0.010 |
Why?
| Anti-Inflammatory Agents | 1 | 2005 | 175 | 0.010 |
Why?
| Exons | 1 | 2003 | 105 | 0.010 |
Why?
| Thyroid Gland | 1 | 2003 | 96 | 0.010 |
Why?
| Luminescent Measurements | 1 | 2002 | 18 | 0.010 |
Why?
| Microsatellite Repeats | 1 | 2002 | 46 | 0.010 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2002 | 54 | 0.010 |
Why?
| Family | 1 | 2003 | 191 | 0.010 |
Why?
| Monitoring, Intraoperative | 1 | 2002 | 66 | 0.010 |
Why?
| Body Mass Index | 1 | 2005 | 712 | 0.010 |
Why?
| Pain | 1 | 2004 | 405 | 0.010 |
Why?
| Liver | 1 | 2005 | 1226 | 0.010 |
Why?
|
|
Ambrogini's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|